This Cathie Wood Growth Stock Could Soar by 93%, According to Wall Street
To say that Exact Sciences (NASDAQ: EXAS) hasn't performed well on the stock market this year would be an understatement. Shares of the cancer-focused biotech are down by 41%. However, the healthcare company still has some fans on Wall Street.
Cathie Wood is one of them. The investment firm she heads, Ark Invest, holds over 330,000 shares of Exact Sciences. She isn't the only one who isn't giving up on the company. Analysts on Wall Street have set an average price target of $83.46, representing a potential upside of 93% over its current stock price.
Can Exact Sciences bounce back and hit this price target in the next 12 months?
Source Fool.com